Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Cancer Chemotherapy and Pharmacology
Erschienen in: Cancer Chemotherapy and Pharmacology 4/2005

01.04.2005 | Original Article

Biochemical modulation of cytarabine triphosphate by clofarabine

verfasst von: Todd Cooper, Mary Ayres, Billie Nowak, Varsha Gandhi

Erschienen in: Cancer Chemotherapy and Pharmacology | Ausgabe 4/2005

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Clofarabine has proven to be effective in the treatment of adult and pediatric acute myelogenous leukemia (AML). To investigate if clofarabine could be used with success in biochemical modulation strategies, we investigated the biochemical modulation of cytarabine triphosphate (ara-CTP) by clofarabine in a myeloid leukemia cell line and the effect of this combination on cytotoxicity.

Experimental design

K562 cells were incubated with clofarabine and ara-C either sequentially or simultaneously to evaluate the combination effect on their phosphorylated metabolites. Clonogenic assays were used to determine the cytotoxicity of each agent alone and in combination. Deoxynucleotide analysis was performed to assess the effect of clofarabine on dNTPs.

Results

Clofarabine added either simultaneously or in sequence increased ara-CTP accumulation. The maximal modulation of ara-CTP accumulation occurred with 1 μM clofarabine. This level was achieved at the maximum tolerated dose for adult and pediatric patients with AML. With 10 μM ara-C alone, 86 μM ara-CTP had accumulated after 3 h. The optimal sequence for the drug combination, i.e., clofarabine followed 4 h later by ara-C, resulted in 248 μM ara-CTP at 3 h. Clofarabine accumulated maximally in the monophosphate form. Preincubation with ara-C did not affect the triphosphate form, but it lowered clofarabine monophosphate. Clofarabine resulted in the intracellular decrease of dATP and dGTP levels. Clonogenic assays revealed that the combination of clofarabine and ara-C produced synergistic killing of myeloid leukemia cells.

Conclusions

These findings demonstrate that combination of clofarabine followed by ara-C results in a biochemical modulation of ara-CTP and synergistic cell kill. These studies provide a compelling rationale for clinical trials using this combination regimen for adult and pediatric patients with AML.
Literatur
1.
Albertioni F, Lindemalm S, Reichelova V, Pettersson B, Erikson S, Juliusson G, Liliemark JO (1998) Pharmacokinetics of cladribine in plasma and its 5′-monophosphate and 5′-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. Clin Cancer Res 4:653–658PubMed
2.
Avramis VI, Wiersma S, Krailo MD, Ramilo-Torno LV, Sharpe A, Liu-Mares W, Kowck R, Reaman GH, Sato JK, The Children’s Cancer Group (1998) Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. Clin Cancer Res 4:45–52PubMed
3.
Carson DA, Wasson DB, Esparaza LM, Carrera CJ, Kipps TJ, Cottam HB (1992) Oral antilymphocyte activity and induction of apoptosis by 2-chloro-2′arabino-flouro-2′deoxyadenosine. Proc Natl Acad Sci U S A 89:2970–2974PubMed
4.
Crews K, Gandhi V, Srivasta D, Razzouk B, Tong X, Behm F, Plunkett W, Raimondi S, Pui C, Rubnitz J, Stewart C, Ribeiro R (2002) Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia. J Clin Oncol 20:4217–4223CrossRefPubMed
5.
Danhauser L, Plunkett W, Keating M, Cabanillas F (1986) 9-beta-D-arabinofuranosyl-2-fluoroadenine 5’-monophosphate pharmacokinetics in plasma and tumor cells of patients with relapsed leukemia and lymphoma. Cancer Chemother Pharmacol 18:145–152
6.
Estey EH, Keating MJ, McCredie KB, Freireich EJ, Plunkett W (1990) Cellular ara-CTP pharmacokinetics, response, and karyotype in newly diagnosed acute myelogenous leukemia. Leukemia 4:95–99PubMed
7.
Faderl S, Gandhi V, O’Brien S, Bonate P, Cortes G, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FG, Du M, Kwari M, Keating MJ, Plunkett W, Kantarjian H (2004) Results of a phase 1–2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood (in press)
8.
Fleischhack G, Hasan C, Graf N, Mann G, Bode U (1998) IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. Br J Haematol 102:647–655CrossRefPubMed
9.
Gandhi V, Plunkett W (1998) Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 48:329–334
10.
Gandhi V, Nowak B, Keating MJ, Plunkett W (1989) Modulation of arabinosylcytosine metabolism by arabinosyl-2-fluoroadenine in lymphocytes from patients with chronic lymphocytic leukemia: implications for combination therapy. Blood 74:2070–2075PubMed
11.
Gandhi V, Kemena A, Keating MJ, Plunkett W (1992) Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia. Cancer Res 52:897–903
12.
Gandhi V, Estey E, Keating MJ, Plunkett W (1993) Fludarabine potentiates metabolism of arabinosylcytosine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 11:116–124PubMed
13.
Gandhi V, Kemena A, Keating MJ, Plunkett W (1993) Cellular pharmacology of fludarabine triphosphate in chronic lymphocytic leukemia cells during fludarabine therapy. Leuk Lymphoma 10:49–56PubMed
14.
Gandhi V, Robertson LE, Keating MJ, Plunkett W (1994) Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 34:30–36
15.
Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W (2003) Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 9:6335–6342PubMed
16.
Ghaddar HM, Plunkett W, Kantarjian HM, Pierce S, Freireich EJ, Keating MJ, Estey EH (1994) Long-term results following treatment of newly diagnosed acute myelogenous leukemia with continuous-infusion high-dose cytosine arabinoside. Leukemia 8:1269–1274PubMed
17.
Hwang TL, Yung WK, Estey EH, Fields WS (1985) Central nervous system toxicity with high-dose ara-C. Neurology 35:1475–1479PubMed
18.
Jeha S, Gandhi V, Chan KW, McDonald L, Ramirez I, Madden R, Rytting M, Keating M, Plunkett W, Kantarjian H (2004) Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia. Blood 103:784–789CrossRefPubMed
19.
Kantarjian H, Estey EH, Plunkett W, Keating MJ, Walters RS, Iacoboni S, McCredie KB, Freireich EJ (1986) Phase I–II and pharmacologic studies of high-dose cytosine arabinoside in refractory leukemia. Am J Med 81:387–394CrossRefPubMed
20.
Kantarjian HM, Gandhi V, Cortes J, Verstovsek S, Du M, Garcia-Manero G, Giles F, Faderl S, O’Brien S, Jeha S, Davis J, Shaked Z, Craig A, Keating M, Plunkett W, Freireich EJ (2003) Phase II clinical and pharmacology study of clofarabine in patients with refractory or relapsed acute leukemia. Blood 102:2379–2386CrossRefPubMed
21.
Kantarjian HM, Gandhi V, Kozuch P, Faderl S, Giles F, Cortes J, O’Brien S, Ibrahim N, Khuri F, Du M, Rios MB, Jeha S, McLaughlin P, Plunkett W, Keating M (2003) Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers. J Clin Oncol 21:1167–1173CrossRefPubMed
22.
Keating MJ, O’Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freirech EJ, Estey E, Kantarjian H (1998) Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165–1171PubMed
23.
Kemena A, Gandhi V, Shewach DS, Keating MJ, Plunkett W (1992) Inhibition of fludarabine metabolism by arabinosylcytosine during therapy. Cancer Chemother Pharmacol 31:193–199
24.
Krance RA, Hurwitz CA, Head DR, Raimondi SC, Behm FG, Crews KR, Srivastava DK, Mahmoud H, Roberts WM, Tong X, Blakley RL, Ribeiro RC (2001) Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol 19:2804–2811PubMed
25.
Kufe D, Spriggs D, Egan EM, Munroe D (1984) Relationships among ara-CTP pools, formation of (ara-C) DNA, and cytotoxicity of human leukemic cells. Blood 64:54–58PubMed
26.
Marcucci G, Byrd JC, Dai G, Klisovic MI, Kourlas PJ, Young DC, Cataland SR, Fisher DB, Lucas D, Chan KK (2003) Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 101:425–432CrossRefPubMed
27.
Momparler RL, Fischer GA (1968) Mammalian deoxynucleoside kinase. I. Deoxycytidine kinase: purification, properties, and kinetic studies with cytosine arabinoside. J Biol Chem 243:4298–4304PubMed
28.
Montgomery JA, Shortnacy-Fowler AT, Clayton SD, Riordan JM, Secrist JA (1983) Synthesis and biologic activity of 2′ fluoro-2-halo derivatives of 9-β-d-arabinofuranosyladenine. Biochem Biophys Res Commun 113:35–43PubMed
29.
Parker WB, Shaddix SC, Chang CH, White EL, Rose LM, Brockman RW, Shortnacy AT, Montgomery JA, Secrist JA III, Bennett LL Jr (1991) Effects of 2-chloro-9-(2-deoxy-2-flouro-b-d-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 51:2386–2394
30.
Parker WB, Bapat AR, Shen JX, Townsend AJ, Cheng YC (1998) Interaction of 2-halogenated dATP analogs (F, Cl, and Br) with human DNA polymerases, DNA primase, and ribonucleotide reductase. Mol Pharmacol 34:485–491
31.
Parker WB, Shaddix SC, Rose LM, Waud WR, Shewach DS, Tiwari KN, Secrist JA III (1999) Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl), 2-chloro-9-(2-deoxy-2-fluoro-β-d-ribofuranosyl) adenine, 2-chloro-9-(2-deoxy-2, 2-difluoro-β-ribofuranosyl) adenine in CEM cells. Mol Pharmacol 55:515–520PubMed
32.
Piro LD, Carrera CJ, Carson DA, Beutler E (1990) Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl J Med 322:1117–1121PubMed
33.
Rodriguez CO Jr, Plunkett W, Paff MT, Du M, Nowak B, Ramakrishna P, Keating MJ, Gandhi V (2000) A high-pressure liquid chromatography method for the determination and quantitation of arabinosylguanine triphosphate and fludarabine triphosphate in human cells. J Chromatogr B 745:421–430
34.
Santana VM, Hurwitz CA, Blakley RL, Crom WR, Luo X, Roberts WM, Ribeiro R, Mahmoud H, Krance RA (1994) Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia. Blood 84:1237–1242PubMed
35.
Schiffer CA (2001) Acute myeloid leukemia in adults: where do we go from here? Cancer Chemother Pharmacol [Suppl] 48:S45–S52
36.
Seymour JF, Huang P, Plunkett W, Gandhi V (1996) Influence of fludarabine on pharmacokinetics of cytarabine: implications for a continuous infusion schedule. Clin Cancer Res 2:653–658PubMed
37.
Sherman PA, Fyfe FA (1989) Enzymatic assay for deoxynucleotide triphosphates using synthetic oligonucleotides as template primer. Anal Biochem 180:222–229PubMed
38.
Spasokoukotskaja T, Sasvari-Szekely M, Keszler G, Albertioni F, Eriksson S, Staub M (1999) Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur J Cancer 35:1862–1867
39.
Virchis A, Koh M, Rankin P, Mehta A, Potter M, Hoffbrand AV, Prentice HG (2004) Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes. Br J Haematol 124:26–32PubMed
40.
Xie KC, Plunkett W (1995) Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl) adenine in human lymphoblastoid cells. Cancer Res 55:2847–2852
41.
Xie KC, Plunkett W (1996) Deoxynucleotide pool deletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl) adenine. Cancer Res 56:3030–3037
Metadaten
Titel
Biochemical modulation of cytarabine triphosphate by clofarabine
verfasst von
Todd Cooper
Mary Ayres
Billie Nowak
Varsha Gandhi
Publikationsdatum
01.04.2005
Erschienen in
Cancer Chemotherapy and Pharmacology / Ausgabe 4/2005
Print ISSN: 0344-5704
Elektronische ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-004-0906-y

Weitere Artikel der Ausgabe 4/2005

Cancer Chemotherapy and Pharmacology 4/2005 Zur Ausgabe

Original Article

Interactions of carboxypeptidase G2 with 6S-leucovorin and 6R-leucovorin in vitro: implications for the application in case of methotrexate intoxications

Original Article

Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O6-benzylguanine

Original Article

Gefitinib (“Iressa”, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells

Original Article

Isolated pelvic perfusion: plasma pharmacokinetics depend primarily on drug dosage and not the type of drug

Original Article

Phase I study of weekly (day 1 and 8) docetaxel in combination with capecitabine in patients with advanced solid malignancies

Short Communication

Bioavailability and pharmacokinetics of the investigational anticancer agent XK469 (NSC 698215) in rats following oral and intravenous administration

Neu im Fachgebiet Onkologie

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise